Author: Mark Newman

Share

Pharma Friday – May 15, 2026

An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Revvity Receives FDA Clearance for Total Testosterone Assay Enabling Comprehensive Automated Testosterone Testing Solution On May 13, Revvity, Inc., through its subsidiary, Immunodiagnostic Systems (IDS), today announced that it received clearance from the U.S. Food and Drug Administration (FDA) for its...
Share

ENDO 2026 Preview: Beyond Basic DXA

At ENDO 2026, taking place June 13 – 16 in Chicago, “Beyond Basic DXA” is set to challenge how clinicians think about bone health assessment. Angela M. Cheung, MD, PhD, a professor of medicine at the University Health Network and the University of Toronto, will lead “Beyond Basic DXA” on Day 4 (Monday, June 15),...
Share

Widespread Chemicals in Plastics May Be Linked to Developmental Delays in Baby Girls

Exposure to common endocrine-disrupting chemicals (EDCs) during pregnancy may significantly alter the reproductive development of female infants during their first months of life, according to a new study published in The Journal of Clinical Endocrinology & Metabolism. Researchers found that daughters of women with higher concentrations of certain chemicals in their systems during pregnancy exhibited...
Share

Polyendocrine Metabolic Ovarian Syndrome: New Name to Improve Diagnosis and Care of Condition Affecting 170 Million Women Worldwide 

Global effort changes the name of a significant women’s health condition that was misunderstood to be ‘all about ovarian cysts’ Polyendocrine Metabolic Ovarian Syndrome (PMOS) is the new name for the condition previously known as Polycystic Ovary Syndrome (PCOS), which impacts one in eight, or more than 170 million women worldwide.  More than 50 patient and professional organizations, including the Endocrine...
Share

Strategic Shifts: New Research Defines Best Ways to Switch Osteoporosis Meds

Effective long-term management of osteoporosis requires a carefully choreographed sequence of medications, as certain drug transitions can significantly enhance or inadvertently undermine bone density, according to a clinical review published by researchers at Aarhus University. The article, “Approach to the Patient—Transitions in Osteoporosis Therapy,” appearing in The Journal of Clinical Endocrinology & Metabolism, emphasizes that...
Share

Adrenaline Overload: Rare Adrenal Tumors Linked to Hidden Bone Loss

Rare neuroendocrine tumors that flood the body with stress hormones like adrenaline do more than spike blood pressure; they may also be quietly degrading the patient’s skeletal system, according to a comprehensive review published by researchers at the National Institutes of Health (NIH). Titled, “Effects of Catecholamines on Bone and Mineral Metabolism in Patients with...
Share

Remembering Endocrine Society Past-President, Delbert A. Fisher, MD

Delbert A. Fisher, past-president of the Endocrine Society and former editor of The Journal of Clinical Endocrinology & Metabolism, passed away March 4, 2026, at the age of 97. Fisher was a pediatric endocrinologist best known for his work in delineating fetal and newborn thyroid physiology, which led to the launch of newborn screening for...